News | February 17, 2026
Indian pharma market grew 10.2% yoy in January 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Company to launch product after the expiry of semaglutide patent in India
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated
